Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Encochleated amphotericin B - Matinas BioPharma

Next Previous
Drug Profile

Encochleated amphotericin B - Matinas BioPharma

Alternative Names: CAmB; MAT-2203

Latest Information Update: 23 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aquarius Biotechnologies
  • Developer Aquarius Biotechnologies; Matinas BioPharma
  • Class Antifungals; Antiprotozoals; Macrolides
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cryptococcosis
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Cryptococcosis
  • Phase II Candidiasis; Vulvovaginal candidiasis
  • Preclinical Aspergillosis; Zygomycosis
  • No development reported Visceral leishmaniasis
  • Discontinued Mycoses

Most Recent Events

  • 14 Aug 2024 Matinas BioPharma enters into a non-binding term sheet with a single partner for global licensing rights to develop, manufacture and commercialize Encochleated amphotericin B
  • 24 Jun 2024 Matinas Biopharma announces intention to submit NDA for Invasive bronchopulmonary aspergillosis
  • 24 Jun 2024 Updated efficacy data from compassionate use expanded access program in Fungal infections released by Matinas Biopharma

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top